Cytokinetics Inc [CYTK] stock prices are up 0.17% to $41.29 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 9.20% over the last week, with a monthly amount drifted -4.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on April 24, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $55. Previously, Citigroup started tracking the stock with Buy rating on February 07, 2025, and set its price target to $86. On January 22, 2025, Stifel initiated with a Buy rating and assigned a price target of $80 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $80 on November 08, 2024. Goldman downgraded its rating to a Neutral and reduced its price target to $60 on August 13, 2024. UBS downgraded its rating to Neutral for this stock on January 24, 2024, and upped its price target to $92. In a note dated January 05, 2024, Morgan Stanley downgraded an Equal-Weight rating on this stock and boosted its target price from $60 to $90.
The stock price of Cytokinetics Inc [CYTK] has been fluctuating between $32.74 and $68.44 over the past year. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $41.29 at the most recent close of the market. An investor can expect a potential return of 47.74% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
The Cytokinetics Inc [NASDAQ:CYTK] reported sales of 18.47M for trailing twelve months, representing a surge of 912.38%. Gross Profit Margin for this corporation currently stands at -8.9% with Operating Profit Margin at -29.03%, Pretax Profit Margin comes in at -31.91%, and Net Profit Margin reading is -31.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is 5.4 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-5.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.67 points at the first support level, and at 40.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.70, and for the 2nd resistance point, it is at 42.11.
Ratios To Look Out For
It’s worth pointing out that Cytokinetics Inc [NASDAQ:CYTK]’s Current Ratio is 6.17. Further, the Quick Ratio stands at 6.17, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 266.45.
Transactions by insiders
Recent insider trading involved Blum Robert I, President & CEO, that happened on Apr 29 ’25 when 5000.0 shares were sold. EVP Research & Development, Malik Fady Ibraham completed a deal on Apr 22 ’25 to sell 2000.0 shares. Meanwhile, Director WIERENGA WENDALL sold 20000.0 shares on Apr 21 ’25.
